Trevi Therapeutics (NASDAQ:TRVI) Upgraded to “Buy” by Zacks Investment Research


Share on StockTwits

Zacks Investment Research upgraded shares of Trevi Therapeutics (NASDAQ:TRVI) from a hold rating to a buy rating in a research note published on Wednesday, Zacks.com reports. The brokerage currently has $3.25 target price on the stock.

According to Zacks, “Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in patients with Parkinson’s disease. Trevi Therapeutics Inc. is based in New Haven, Connecticut. “

TRVI remained flat at $$3.00 on Wednesday. The company’s stock had a trading volume of 31,996 shares, compared to its average volume of 62,837. The stock’s 50-day moving average is $2.89 and its 200 day moving average is $3.97. The firm has a market cap of $55.14 million, a PE ratio of -2.01 and a beta of 0.10. Trevi Therapeutics has a 12-month low of $1.33 and a 12-month high of $8.50.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.41) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.18. Equities analysts forecast that Trevi Therapeutics will post -2.14 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Trevi Therapeutics stock. Bridgeway Capital Management Inc. raised its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 33.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 100,000 shares of the company’s stock after acquiring an additional 25,000 shares during the period. Bridgeway Capital Management Inc. owned approximately 0.55% of Trevi Therapeutics worth $658,000 as of its most recent SEC filing. 73.33% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Its Haduvio (nalbuphine ER), which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus.

Read More: Dead Cat Bounce

Get a free copy of the Zacks research report on Trevi Therapeutics (TRVI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.